selected publications
-
Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2026
Academic Article
GET IT
Times cited: 4 - Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US. Future oncology (London, England). 2025 Academic Article GET IT
-
The future of follicular lymphoma management: strategies on the horizon.
Blood.
2025
Information Resource
GET IT
Times cited: 1 -
Follicular lymphoma grade 3B: low grade, high grade or should we skip the grade?.
Haematologica.
2023
Editorial Article
GET IT
Times cited: 4 -
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL.
Blood.
2023
Academic Article
GET IT
Times cited: 62 -
Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma.
Molecular cancer therapeutics.
2022
Academic Article
GET IT
Times cited: 5 -
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
Blood.
2022
Academic Article
GET IT
Times cited: 36 -
Biomarker-driven management strategies for peripheral T cell lymphoma.
Journal of hematology & oncology.
2020
Information Resource
GET IT
Times cited: 39 -
CCL2/CCR2 Regulates the Tumor Microenvironment in HER-2/neu-Driven Mammary Carcinomas in Mice.
PloS one.
2016
Academic Article
GET IT
Times cited: 53 -
IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.
PloS one.
2015
Academic Article
GET IT
Times cited: 98